Replies to post #269811 on Avid Bioservices Inc (CDMO)

[geocappy1]

Yes, so far I would say we are in the less when it comes to overcoming the suppressed immune system in academia, pre-clinical, and KOl discussions not using the word bavi. Unfortunately, we have not shown an accepted human version that can be monetized.

[biopharm]

9-13-16 4:30pm: Speaker: Jeff Hutchins (VP/Prelin.Res., Peregrine), “Overriding Immune Suppression and Increasing TILs Through Blockade of the Phosphatidylserine Signaling Pathway”

TIL's measured in a simple blood test must have a direct correlation to the level of cancer one has and all part of ...hmmm, how did Patrick Soon-Shiong call it ==> Predictive Protein Pathways. Flipped PS must be targeted and lets go Peregrine, I have not heard about any collaboration with Tesaro as of yet.

slide 3 of 17
Potential ligands:
•galectin-9
•phosphatidylserine
•HMGB1
•CEACAM-1

slide 6 of 17
Advanced stage NSCLC correlates with increased TIM-3 and LAG-3 expression on PD-1 hi cells

immune-checkpoint.com/wp-content/uploads/sites/24/2016/03/Day-1-1200-Andrew-Furgeson.pdf

--------------

Importantly, additional checkpoint molecules, such as T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and lymphocyte activation gene 3 (LAG3), have been found over-expressed in cells44–46 and their potential use in immunotherapy has been reported in pre-clinical studies.47–49 Special attention has been paid to LAG-3, which is up-regulated by T cells exhausted by chronic antigen exposure and especially over-expressed in tumour-infiltrating lymphocytes (TILs).45,46 LAG-3 and PD-1, are co-expressed by TILs,45 and display synergistic functions at controlling immunological homeostasis. It has been recently shown that dual inhibition of both receptors decreased tumour growth and enhanced anti-tumour immunity.50 Because dual treatment promotes tumour-specific immune responses, with reduced unspecific or self-antigen-specific responses, it can be considered as an interesting strategy for further evaluation in the clinic. Along these lines, a phase I clinical trial is in progress to assess the safety and tolerability of the anti-LAG-3, BMS-986016, alone and in combination with anti-PD-1 in subjects with advanced solid tumours (NCT01968109).

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427384/


-------------

Keith Wilcoxen

Experience
Head of Strategic Partnerships, R&D
TESARO, Inc.
July 2016 – Present (2 months)Waltham, MA 02451

Our group aims to establish impactful partnerships with leading oncology and immune-oncology external investigators, researchers and drug hunting discovery groups (academic or biotechnology) to develop therapeutic concepts and new drugs to advance into human clinical trials.
..
..
https://www.linkedin.com/in/keith-wilcoxen-0b3322

--------------

We know in the past Tesaro was a PS targeting supporter and after seeing the dots connecting TILs and Jeff Hutchins up and coming presentation... things can get interesting quick, especially since David Mott just so happens to be involved again (also was at Ambit) and since Daiichi Sankyo jumps at that buy we wait for further confirmation of all the other collaborations on goings. I wonder what deal Tesaro will be part of.... just an educated guess but something seems to be ready after seeing Keith making it up to Head of strategic partnerships and since they backed PS Targeting early on.

On final note: I wonder if BMS-986016 has been given a name yet. Dr. Wolchok working with it as well... and again, things can change quickly in Tustin.

https://www.mskcc.org/cancer-care/clinical-trials/14-010

https://clinicaltrials.gov/ct2/results?term=BMS-986016&Search=Search